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Abstract
Background
Impaired renal function causes dyslipidemia that contributes to elevated cardiovascular risk
in patients with chronic kidney disease (CKD). The proprotein convertase subtilisin/kexin
type 9 (PCSK9) is a regulator of the LDL receptor and plasma cholesterol concentrations.
Its relationship to kidney function and cardiovascular events in patients with reduced glo-
merular filtration rate (GFR) has not been explored.
Methods
Lipid parameters including PCSK9 were measured in two independent cohorts. CARE FOR
HOMe (Cardiovascular and Renal Outcome in CKD 2–4 Patients—The Forth Homburg eval-
uation) enrolled 443 patients with reduced GFR (between 90 and 15ml/min/1.73 m2) referred
for nephrological care that were prospectively followed for the occurrence of a composite car-
diovascular endpoint. As a replication cohort, PCSK9 was quantitated in 1450 patients with
GFR between 90 and 15ml/min/1.73 m2 enrolled in the Ludwigshafen Risk and Cardiovascu-
lar Health Study (LURIC) that were prospectively followed for cardiovascular deaths.
Results
PCSK9 concentrations did not correlate with baseline GFR (CARE FOR HOMe: r = -0.034;
p = 0.479; LURIC: r = -0.017; p = 0.512). 91 patients in CARE FOR HOMe and 335 patients
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in LURIC reached an endpoint during a median follow-up of 3.0 [1.8–4.1] years and 10.0
[7.3–10.6] years, respectively. Kaplan-Meier analyses showed that PCSK9 concentrations
did not predict cardiovascular events in either cohort [CARE FOR HOMe (p = 0.622);
LURIC (p = 0.729)]. Sensitivity analyses according to statin intake yielded similar results.
Conclusion
In two well characterized independent cohort studies, PCSK9 plasma levels did not corre-
late with kidney function. Furthermore, PCSK9 plasma concentrations were not associated
with cardiovascular events in patients with reduced renal function.
Introduction
Patients with decreased glomerular filtration rate (GFR) are at high risk for cardiovascular
(CV) events [1]. Their elevated CV risk is caused by a complex interplay of non-traditional risk
factors, such as inflammation [2], dysregulated calcium-phosphate metabolism [3] and tradi-
tional risk factors such as dyslipidemia and hypertension [4]. Dyslipidemia in patients with
impaired renal function is characterized by qualitative changes in cholesterol homeostasis [5]
and reverse cholesterol transport [6], and quantitative changes of lipid parameters [7]. Progres-
sive kidney function loss is accompanied by a rise of triglycerides and VLDL-cholesterol
(VLDL-C); at the same time total cholesterol, HDL-cholesterol (HDL-C) and LDL-cholesterol
(LDL-C) decrease [7]. Specifically, baseline mean LDL-C in the large statin trials in chronic
kidney disease (CKD) patients were in the relatively low range of 100–120 mg/dl [8–10]. The
underlying mechanisms of CKD associated dyslipidemia and especially the reason for low
LDL-C serum concentrations are not fully understood.
Hepatic uptake of LDL-C by the LDL receptor is the major route of LDL clearance from the
blood. In the last decade a new, central regulator of LDL receptor expression, namely proprotein
convertase subtilisin/kexin type 9 (PCSK9), has been identified (as reviewed in [11]). PCSK9
facilitates LDL receptor degradation and inhibits the receptor’s recycling to the membrane. Gain-
of-function mutations of PCSK9 have been linked with elevated LDL-C whereas loss-of-function
mutations are tied to low LDL-C and reduced CV risk. Thus, PCSK9 has become a promising
drug target in CVmedicine with several drug development programs currently underway. As evi-
denced by the statin trials in hemodialysis patients (4D and AURORA) [9,10] and other trials
aiming to improve CV prognosis [12], patients with chronic kidney disease differ from other
individuals with high CV risk. The reasons for this difference are not fully understood. In this
respect it is unknown whether kidney function affects PCSK9 levels. In addition, it is not known
whether PCSK9 levels correlate with CV risk in patients with decreased GFR.
In the current study we therefore aimed to analyze the relationship between kidney
function and PCSK9. Furthermore, we asked whether PCSK9 predicts CV risk in patients with
decreased glomerular filtration rate. The results of the CARE FOR HOMe study (Cardiovascu-
lar and Renal Outcome in CKD 2–4 Patients—The Forth Homburg evaluation) were con-
firmed in the Ludwigshafen Risk and Cardiovascular Health Study (LURIC).
Materials and Methods
PCSK9 plasma concentrations were assessed in the CARE FOR HOMe (Cardiovascular and
Renal Outcome in CKD 2–4 Patients—The Forth Homburg evaluation) study. The results
PCSK9 and Decreased GFR
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were confirmed in the LURIC study (Ludwigshafen Risk and Cardiovascular Health Study).
Both studies were conducted in accordance with the Declaration of Helsinki.
Study description–CARE FOR HOMe
The CARE FOR HOMe study is an ongoing, prospective cohort study in CKD patients which
aims to characterize cardio-renal interactions [13–15]. Recruitment started in September 2008
with an average recruitment rate of 100 patients per year. Study participants were referred for
nephrological care to the outpatient clinic of the Department of Internal Medicine IV of Saar-
land University Medical Centre. Patients with CKD GFR categories 2–4, corresponding to a
glomerular filtration rate (GFR) between 90 and 15 ml/min/1.73 m2, were invited to partici-
pate. Unstable clinical status (active malignancy, systemic infection), acute kidney injury and
intake of immunosuppressant drugs were defined as exclusion criteria.
Information on co-morbidity was gathered by a standardized questionnaire and confirmed
by chart review. Pre-existent cardiovascular disease was defined as a history of myocardial
infarction, coronary artery angioplasty / stenting / bypass surgery, major stroke, carotid endar-
terectomy / stenting, nontraumatic lower extremity amputation, or lower limb artery angio-
plasty / stenting / bypass surgery. Patients with self-reported or physician-reported diabetes
mellitus, with a fasting blood glucose level of126 mg/dl and / or with current use of hypogly-
cemic medication, were defined as diabetic. Patients were categorized as active smokers if they
were current smokers or had stopped smoking< 1 month before entry into the study.
Blood pressure was measured after 5 mins of rest with an automated blood pressure record-
ing apparatus (GE Carescape DINAMAP V100; GE Healthcare). Body mass index (BMI) was
calculated as weight (kg)/[height (m)]2.
The local Ethics Committee (Ethikkommision der Aerztekammer des Saarlandes for CARE
FOR HOMe and Ethikkommision der Aerztekammer von Rheinland-Pfalz) approved the
study and all participants gave their written informed consent.
Laboratory measurements in CARE FOR HOMe
In CARE FOR HOMe participants, we obtained blood samples after an overnight fast. All rou-
tine laboratory measurements in CARE FOR Home were performed at the core facility for
Clinical Chemistry and Laboratory Medicine of Saarland University Medical Centre. Fasting
PCSK9 concentrations were measured by enzyme-linked immunosorbent assay using the Cir-
culex Human PCSK9 ELISA Kit (CY-8079, CycLex, Japan) in diluted (1:100) fasting plasma
samples according to the manufacturer’s instructions. A seven-point standard curve (range
0.16 to 10 ng/ml) was created using lyophilized human PCSK9.
End-points in CARE FOR HOMe
All CARE FOR HOMe patients were invited annually for follow-up examinations. The com-
posite CV end-point was defined as the first occurrence of any of the following: acute myocar-
dial infarction; surgical or interventional coronary / cerebrovascular / peripheral-arterial
revascularization; stroke with symptoms 24 hours, amputation above the ankle; or death of
any cause. Myocardial infarction was defined according to the Joint ESC/ACCF/AHA/WHF
task force consensus criteria.[16] Outcome adjudication was performed by two physicians
blinded to baseline PCSK9 levels. In case of disagreement, a third physician gave an assessment
blinded to those of the previous two doctors. For all events confirmatory medical documenta-
tion was obtained. This outcome adjudication process has been described previously.[17]
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Study description–LURIC
Methods and the study population of LURIC have been described in detail earlier.[18] The
LURIC study included 3,316 patients referred for coronary angiography between 1997 and
2000 at a tertiary care centre in south-western Germany. Clinical indications for angiography
were chest pain or a positive non-invasive stress test suggestive of myocardial ischemia. To
limit clinical heterogeneity, individuals suffering from acute illnesses other than acute coronary
syndrome, chronic non-cardiac diseases and a history of malignancy within the five past years
were excluded. Study participants were followed-up for a median of 10 years. 1462 LURIC par-
ticipants had PCSK9 measurements and a GFR between 90 and 15 ml/min/1.73m2 estimated
by the MDRD formula corresponding to the GFR inclusion criterion of CARE FOR HOMe. Of
those, 1450 had complete data on vital status and causes of death.
Laboratory measurements in LURIC
Fasting blood samples were collected in the early morning with patients in the supine position.
Routine laboratory parameters were measured on a daily basis as previously described[18]. The
lipoproteins were separated using a combined ultracentrifugation–precipitation method (β-
quantification). Cholesterol and triglycerides were measured with enzymatic reagents from
WAKO (Neuss, Germany) on a WAKO 30 R analyser. Apolipoproteins A-I, and B were mea-
sured by turbidimetry (Rolf-Greiner Biochemica, Flacht, Germany). Creatinine was measured
with the Jaffé method on a Hitachi 717 analyzer (Roche Diagnostics, Mannheim, Germany).
The CRP concentrations were determined using immunonephelometry (N High Sensitivity
CRP, Dade Behring, Marburg, Germany). Total PCSK9 was measured using the Quantikine
Human PCSK9 sandwich immunoassay (R&D, Minneapolis, MN, USA).
Endpoints in LURIC
Information on vital status was obtained from local registries No patient was lost to follow-up.
Causes of death were determined using death certificates. Patients were classified into those
who died of cardiovascular versus those who died of non-cardiovascular causes. Cardiovascular
death included sudden death, fatal myocardial infarction, death due to congestive heart failure,
death immediately after intervention to treat coronary heart disease (CHD), fatal stroke, and
other causes of death due to CHD. In LURIC STEMI was diagnosed if typical ECG changes
were present along with prolonged chest pain, refractory to sublingual nitrates and / or enzyme
or troponin T elevations (>0.1 mg/L). Non-ST elevation MI (NSTEMI) was diagnosed, if
symptoms and/or troponin T criteria were met without STEMI ECG criteria. This classification
was performed independently by two experienced clinicians who were blinded to the study par-
ticipants. In the case of disagreement or uncertainty, a decision was made by one of the LURIC
study principal investigators (W.M.). The adjudication process has been described previously.
[19]
Statistical analysis applied in CARE FOR HOMe and LURIC
Data management and statistical analysis were performed using PASW Statistics 22 (SPSS,
Inc., Chicago, Illinois). Two-sided p values< 0.05 were considered significant.
For clinical data, categorical variables are presented as percentages of patients and were
compared using chi-square or Fisher’s exact tests, as appropriate. Continuous data are
expressed as median and interquartile range and compared using Mann-Whitney U test for
two independent samples or Kruskal-Wallis test for more than two independent samples, fol-
lowed by Jonckheere-Terpstra test for trend. The associations between continuous variables
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were assessed using Spearman correlation testing. Patients were divided into 3 equally sized
groups (tertiles) according to their levels of PCSK9. Kaplan-Meier survival curves were used to
compare event-free survival (i.e., time until first occurrence of the composite endpoint)
between groups. The log-rank test was used to test the hypothesis that at least one of the sur-
vival curves differs from the others. In CARE FOR HOMe Cox proportional hazard models
were calculated to analyze the relationship of lipid parameters (PCSK9, total cholesterol, Apo
A-I, Apo B) with event-free survival after adjustment for GFR, age, mean BP, gender, preva-
lence of CV disease, diabetes mellitus and statin intake; in LURIC Cox proportional models
were built with baseline variables differing between those participants with an event compared
to those without an event (gender, prevalent cardiovascular disease, smoking, diabetes mellitus,
age, BMI, systolic blood pressure, GFR, apo A-I and hsCRP).
Results
PCSK9 concentrations and baseline characteristics
Baseline characteristics of CARE FOR HOMe participants according to tertiles of PCSK9 are
summarized in Table 1.
In the entire cohort, PCSK9 levels weakly correlated with BMI (r = 0.125; p = 0.008), total
cholesterol (r = 0.102; p = 0.031), triglycerides (r = 0.190; p< 0.001), Apo A-I (r = 0.149;
p = 0.002) and Apo B (r = 0.114; p< 0.018), but not with LDL cholesterol (r = 0.051;
p = 0.287) or GFR (r = -0.034; p = 0.479; Fig 1).
Table 1. Baseline characteristics of CARE FORHOMe participants stratified by PCSK9 tertiles.
Total Cohort 1st Tertile 2nd Tertile 3rd Tertile p-value
N = 443 N = 147 N = 149 N = 147
Gender (men) 265 (60%) 101 (69%) 86 (58%) 78 (53%) 0.019
Prevalent CVD (yes) 135 (30%) 42 (29%) 42 (28%) 51 (35%) 0.396
Smoking (yes) 44 (10%) 15 (10%) 13 (9%) 16 (11%) 0.817
Diabetes (yes) 168 (38%) 52 (35%) 57 (38%) 59 (40%) 0.698
Age (years) 67.7 [57.0–74.3] 67.7 [55.7–74.4] 59.6 [69.8–74.5] 65.1 [55.9–73.9] 0.266
BMI (kg/m2) 29.8 [26.1–33.1] 29.2 [25.3–32.7] 29.7 [25.7–33.4] 30.5 [27.1–33.4] 0.035
Mean BP (mmHg) 108 [99–118] 108 [101–119] 109 [98–120] 108 [100–116] 0.756
GFR (ml/min/1.73 m2) 46.1 [33.4–56.7] 46.7 [35.3–57.4] 46.2 [33.2–57.5] 43.4 [32.2–54.6] 0.410
UAE (mg/g creatinine) 35 [8–193] 34 [9–149] 32 [7–181] 41 [8–254] 0.888
PCSK9 (ng/ml) 343 [270–413] 246 [215–270] 343 [323–366] 471 [413–534] <0.001
Total Cholesterol (mg/dl) 188 [162–219] 185 [162–209] 189 [159–224] 195 [166–221] 0.243
HDL Cholesterol (mg/dl) 48 [39–61] 47 [38–61] 49 [41–64] 48 [40–59] 0.620
LDL Cholesterol (mg/dl) 114 [90–138] 114 [89–135] 116 [93–141] 113 [89–140] 0.674
Triglycerides (mg/dl) 135 [97 - 190] 116 [88 - 164] 137 [106 - 200] 156 [107 - 232] < 0.001
Apo A-I (mg/dl) 161 [142–185] 156 [137–182] 161 [144–186] 165 [148–188] 0.049
Apo B (mg/dl) 97 [82–115] 94 [79–110] 98 [80–114] 100 [86–117] 0.118
hsCRP (mg/l) 2.7 [1.2 – 5.3] 2.7 [1.1 - 5.4] 2.6 [1.2 - 5.1] 3.0 [1.2 – 5.6] 0.795
Statin (yes) 216 (49 %) 48 (33%) 79 (53%) 89 (61%) < 0.001
CVD: cardiovascular disease; BMI: body mass index; BP: blood pressure; GFR: glomerular ﬁltration rate; UAE: urinary albumin excretion; PCSK9:
proprotein convertase subtilisin/kexin type 9; Apo A-I, B: apolipoprotein A, B; hsCRP: high-sensitivity C-reactive protein. Data are presented as numbers
(percentages) or median and interquartile range as appropriate.
doi:10.1371/journal.pone.0146920.t001
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Characteristics according to statin intake across categories of kidney
function
216 (49%) out of 443 patients were taking statins. Patients were stratified according to statin
intake across GFR categories. In statin users vs. non-statin users, the proportion of patients
with prevalent CV disease was higher (100/216 vs 35/227; p<0.001) whereas no difference was
found regarding gender distribution (men: 131/216 vs 134/227; p = 0.771), diabetic status (dia-
betics: 91/216 vs 77/227; p = 0.079) and smoking status (20/216 vs 24/227; p = 0.751). Statin
users in comparison to statin non-users were significantly older (67.9 ± 10.2 vs 62.4 ± 13.8 yrs;
p<0.001) and had significantly lower GFR (43.6 ± 15.0 vs 46.9 ± 16.7 ml/min/1.73 m2;
p = 0.031). The other characteristics of the two subgroups were similar. PCSK9 levels did not
differ across GFR categories in statin users (p for trend = 0.350) and statin non-users (p for
trend = 0.292) as shown in Fig 2.
However, within each GFR category statin users had higher PCSK9 concentrations com-
pared to statin non-users (GFR 15–29 ml/min/1.73 m2: p = 0.031; GFR 30–44 ml/min/1.73 m2:
p = 0.170; GFR 45–59 ml/min/1.73 m2: p<0.001; GFR 60–90 ml/min/1.73 m2: p = 0.001).
Clinical follow-up in CARE FOR HOMe
Median follow-up time was 3.0 [1.8–4.1] years, during which 91 patients reached the primary
end-point. Characteristics of patients according event status are summarized in Table 2. No
patient was lost to follow-up. We analyzed the relationship between PCSK9 and CV outcome
by Kaplan-Meier analysis, demonstrating no significant association between tertiles of PCSK9
and CV outcome (Fig 3).
Kaplan-Meier analyses of the subgroups with and without statin treatment were performed
separately; in these sensitivity analyses consistently with the overall cohort no association between
tertiles of PCSK9 (statin users: p = 0.367; statin non-users: p = 0.834) and outcome was seen.
Finally, in multivariate analyses we adjusted for confounders, including lipid parameters
(log PCSK9, total cholesterol, Apo A-I, Apo B), GFR, traditional CV risk factors (age, sex,
Fig 1. Correlation between PCSK9 and estimated glomerular filtration rate (GFR) assessed by
Spearman test.
doi:10.1371/journal.pone.0146920.g001
PCSK9 and Decreased GFR
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Fig 2. Association of PCSK9 with strata of GFR in patients taking statins and patients not on statin
medication; Jonckheere Terpstra test for comparison among statin users, respectively statin non-
users, across GFR strata.
doi:10.1371/journal.pone.0146920.g002
Table 2. Baseline characteristics stratified by event status.
Total Cohort No Event Event p-value
N = 443 N = 352 N = 91
Gender (men) 265 (60%) 201 (57%) 64 (70%) 0.023
Prevalent CVD (yes) 135 (30%) 78 (22%) 57 (63%) <0.001
Smoking (yes) 44 (10%) 33 (9%) 11 (12%) 0.435
Diabetes (yes) 168 (38%) 122 (35%) 46 (51%) 0.007
Age (years) 67.7 [57.0–74.3] 65.5 [55.2–73.7] 72.7 [66.4–77.3] <0.001
BMI (kg/m2) 29.8 [26.1–33.1] 30.0 [26.2–33.4] 28.8 [26.0–32.6] 0.143
Mean BP (mmHg) 108 [99–118] 109 [101–119] 104 [91–115] 0.002
GFR (ml/min/1.73 m2) 46.1 [33.4–56.7] 47.9 [36.8–58.7] 34.3 [26.0–45.2] <0.001
UAE (mg/g creatinine) 35 [8–193] 27 [7–157] 80 [22–315] 0.001
PCSK9 (ng/ml) 343 [270–413] 349 [269–421] 330 [272–409] 0.316
Total Cholesterol (mg/dl) 188 [162–219] 195 [167–223] 171 [150–195] <0.001
HDL Cholesterol (mg/dl) 48 [39–61] 49 [41–63] 44 [36–53] 0.001
LDL Cholesterol (mg/dl) 114 [90–138] 116 [93–140] 100 [82–123] 0.001
Triglycerides (mg/dl) 135 [97–190] 135 [96–195] 132 [97–183] 0.632
Apo A-I (mg/dl) 161 [142–185] 165 [146–189] 148 [132–165] <0.001
Apo B (mg/dl) 97 [82–115] 99 [83–116] 92 [78–105] 0.008
hsCRP (mg/l) 2.7 [1.2–5.3] 2.6 [1.1–4.8] 3.9 [1.6–9.6] 0.003
Statin (yes) 216 (49%) 161 (46%) 55 (60%) 0.014
CVD: cardiovascular disease; BMI: body mass index; BP: blood pressure; GFR: glomerular ﬁltration rate; UAE: urinary albumin excretion; PCSK9:
proprotein convertase subtilisin/kexin type 9; Apo A-I, B:apolipoprotein A, B;hsCRP: high-sensitivity C-reactive protein. Data are presented as numbers
(percentages) or median and interquartile range as appropriate.
doi:10.1371/journal.pone.0146920.t002
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prevalent CV disease) and statin intake; after full adjustment only GFR, age, prevalent CV
disease and diabetes mellitus were independent predictors of CV outcome (Table 3).
Replication of the analysis in the LURIC cohort
Table 4 depicts the baseline characteristics of LURIC participants stratified by tertiles of
PCSK9.
Among all 1450 patients analysed, PCSK9 levels correlated negligibly with Apo A-I
(r = 0.092; p =<0.001), triglycerides (r = 0.084; p<0.001) and with HDL cholesterol
(r = 0.061; p = 0.021) but not with total cholesterol (r = 0.006; p = 0.832), LDL cholesterol (r =
-0.018; p = 0.489), Apo B (r = 0.026; p = 0.321) or GFR (r = -0.017; p = 0.512; Fig 4).
Fig 3. Association of tertiles of PCSK9 with cardiovascular outcome; Kaplan-Meier analysis followed
by log-rank test.
doi:10.1371/journal.pone.0146920.g003
Table 3. Adjusted Cox regression analysis (different models) for cardiovascular events in CARE FORHOMe.
HR Mod1 95% CI p-value HR Mod2 95% CI p-value HR Mod3 95% CI p-value
GFR (ml/min/1.73 m2) 0.974 (0.959, 0.989) 0.001 0.972 (0.957, 0.987) <0.001 0.972 (0.957, 0.987) <0.001
Age (years) 1.045 (1.022, 1.069) <0.001 1.031 (1.007, 1,056) 0.012 1.031 (1.007, 1.056) 0.012
Log PCSK9 0.570 (0.121, 2.685) 0.477 0.330 (0.062, 1.751) 0.193 0.333 (0.060, 1.832) 0.206
Total-C (mg/dl) 0.992 (0.979, 1.004) 0.176 0.994 (0.982, 1.006) 0.298 0.994 (0.982, 1.006) 0.307
Apo A-I (mg/dl) 0.990 (0.980, 1.000) 0.041 0.996 (0.987, 1.006) 0.470 0.997 (0.987, 1.006) 0.483
Apo B (mg/dl) 1.004 (0.984, 1.024) 0.729 1.003 (0.984, 1.022) 0.748 1.003 (0.984, 1.022) 0.745
Mean BP (mmHg) 0.994 (0.979, 1.009) 0.411 0.986 (0.971, 1.001) 0.072 0.986 (0.971, 1.001) 0.072
Gender (male) 1.310 (0.811, 2.115) 0.269 1.311 (0.811, 2.117) 0.269
Prevalent CVD (yes) 3.069 (1.934, 4.870) <0.001 3.078 (1.910, 4.961) <0.001
Diabetes mellitus (yes) 1.616 (1.053, 2.479) 0.028 1.617 (1.053, 2.485) 0.028
Statin (yes) 0.988 (0.606, 1.609) 0.960
GFR: glomerular ﬁltration rate; PCSK9: proprotein convertase subtilisin/kexin type 9; Total-C: total cholesterol; ApoA- I, B: apoliporotein A, B; Mean BP:
mean blood pressure; CVD: cardiovascular disease. Model 1 includes GFR, age, PCSK9, total cholesterol, Apo A-I, Apo B and mean BP. Model 2 adjusts
for the variables of model 1 and for gender, prevalent CVD and diabetes mellitus. Model 3 adjusts for variables of model 2 and for statin intake.
doi:10.1371/journal.pone.0146920.t003
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After stratification of the cohort by intake of statins, only weak associations between PCSK9
and total cholesterol (r = 0.106; p = 0.004), LDL cholesterol (r = 0.100; p = 0.007), Apo B
(r = 0.107; p = 0.004), HDL cholesterol (r = 0.102; p = 0.006), Apo A-I (r = 0.126; p = 0.001)
and triglycerides (r = 0.094; p = 0.011) were seen in patients (n = 729) not on statins. However,
no correlation between PCSK9 and GFR (r = 0.013; p = 0.733) was detectable in those patients
not on statins.
In statin users (n = 721) no correlation between PCSK9 and total cholesterol (r = 0.058;
p = 0.119), LDL cholesterol (r = 0.028; p = 0.448), Apo B (r = 0.046; p = 0.215), triglycerides
(r = 0.041; p = 0.273) or GFR (r = -0.024; p = 0.528) was seen; only a weak association appeared
between PCSK9 and HDL cholesterol (r = 0.093; p = 0.012) and Apo A (r = 0.142; p< 0.001),
respectively.
During a median follow-up time of 10.0 [7.3–10.6] years 497 patients died, of whom 335
patients died from cardiovascular causes; Table 5 summarizes clinical characteristics according
to event status. In Kaplan-Meier analysis, tertiles of PCSK9 were not associated with cardiovas-
cular deaths (p = 0.729; Fig 5).
Separate analyses stratified by statin intake did not yield different results (no statin:
p = 0.772; statin: p = 0.611).
In multivariate Cox-Regression analysis (model adjusting for sex, presence of cardiovascular
disease, smoking status, diabetes mellitus, age, BMI, systolic blood pressure, GFR, apolipopro-
tein A-I and C-reactive protein) male sex (p = 0.020; HR 1.68, 95% CI: [1.024–1.332]), no prev-
alent cardiovascular disease (p = 0.002; HR 0.830, 95% CI: [0.736–0.936]), previous smoking
(p = 0.019; HR 1.162, 95% CI [1.025–1.317]), diabetes mellitus (p<0.001; HR 1.425, 95%
Table 4. Baseline characteristics of LURIC participants stratified by PCSK9 tertiles.
Total Cohort 1st Tertile 2nd Tertile 3rd Tertile p-value
N = 1450 N = 498 N = 470 N = 482
Gender (men) 925 (64%) 362 (73%) 295 (63%) 268 (56%) < 0.001
Prevalent CVD (yes) 994 (69%) 312 (63%) 338 (72%) 344 (71%) 0.002
Smoking (yes) 206 (14%) 76 (15%) 69 (15%) 61 (13%) 0.043
Diabetes (yes) 637 (44%) 206 (41%) 201 (43%) 230 (48%) 0.111
Age (years) 67.0 [59.5–72.5] 66.4 [58.6–71.7] 67.4 [60.0–72.9] 66.9 [59.9–72.5] 0.105
BMI (kg/m2) 27.0 [24.7–29.7] 26.7 [24.7–29.4] 27.0 [24.8–29.9] 27.4 [24.6–29.8] 0.497
Systolic BP (mmHg) 143 [127–159] 143 [126–159] 144 [129–158] 142 [126–161] 0.708
Diastolic BP (mmHg) 81 [73–88] 82 [74–90] 80 [73–89] 81 [73–87] 0.302
GFR (ml/min/1.73 m2) 74.7 [65.0–81.3] 76.5 [65.0–82.3] 73.5 [64.9–80.5] 74.8 [65.1–81.0] 0.155
PCSK9 (ng/ml) 208 [161–264] 146 [123–163] 208 [193–223] 291 [264–334] < 0.001
Total Cholesterol (mg/dl) (mg/dl) 189 [165–215] 188 [166–215] 190 [165–216] 189 [163–215] 0.646
HDL Cholesterol (mg/dl) 37 [31–45] 37 [31–44] 38 [31–45] 38 [31–45] 0.171
LDL Cholesterol (mg/dl) 112 [91–135] 113 [93–135] 112 [89–135] 110 [89–135] 0.833
Triglycerides (mg/dl) 150 [112–202] 140 [109–192] 149 [110–196] 159 [117–214] 0.001
Apo A-I (mg/dl) 127 [113–144] 124 [111–141] 127 [113–147] 129 [114–146] 0.008
Apo B (mg/dl) 103 [87–118] 102 [86–117] 103 [88–118] 103 [87–120] 0.278
hsCRP (mg/l) 3.7 [1.5–9.0] 3.7 [1.5–8.4] 3.7 [1.3–9.1] 3.7 [1.5–9.6] 0.501
Statin (yes) 721 (50%) 164 (33%) 235 (50%) 322 (67%) < 0.001
CVD: cardiovascular disease; BMI: body mass index; BP: blood pressure; GFR: glomerular ﬁltration rate; PCSK9: proprotein convertase subtilisin/kexin
type 9; Apo A-I, B: apolipoprotein A, B; hsCRP: high-sensitivity C-reactive protein. Data are presented as numbers (percentages) or median and
interquartile range as appropriate. P-Values in italics are signiﬁcant by Jonckheere-Terpstra test for trend.
doi:10.1371/journal.pone.0146920.t004
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CI: [1.278–1.589], age per year (p< 0.001; HR 1.024, 95% CI: [1.017–1.030]) and GFR per
1ml/min/1.73m2 (p< 0.001; HR 0.987, 95%CI: [0.982–0.991]) predicted cardiovascular death.
Taken together, results from the independent LURIC study fully support the results
obtained in the CARE FOR HOMe study.
Fig 4. Correlation between PCSK9 and estimated glomerular filtration rate (GFR) assessed by
Spearman test in LURIC participants.
doi:10.1371/journal.pone.0146920.g004
Table 5. Baseline characteristics of LURIC stratified by cardiovascular event status.
Total Cohort Alive CV Death Non CV Death p-value
N = 1450 N = 953 N = 335 N = 162
Gender (men) 925 (64%) 588 (62%) 222 (66%) 115 (71%) 0.042
Prevalent CVD (yes) 994 (69%) 609 (64%) 270 (81%) 115 (71%) <0.001
Smoking (yes) 206 (14%) 151 (16%) 30 (9%) 25 (15%) 0.001
Diabetes (yes) 637 (44%) 344 (36%) 211 (63%) 82 (51%) <0.001
Age (years) 67.0 [59.5–72.5] 64.1 [56.9–70.1] 70.8 [66.0–75.8] 72.1 [66.0–75.6] <0.001
BMI (kg/m2) 27.0 [24.7–29.7] 27.1 [24.8–29.8] 26.7 [24.7–29.8] 26.1 [24.2–29.0] 0.046
Systolic BP (mmHg) 143 [127–159] 141 [124–157] 147 [130–163] 145 [131–163] <0.001
Diastolic BP (mmHG) 81 [73–88] 82 [74–89] 80 [72–88] 79 [73–86] 0.146
GFR (ml/min/1.73 m2) 74.7 [65.0–81.3] 76.4 [67.0–81.8] 70.2 [57.9–78.8] 73.4 [62.9–81.1] <0.001
PCSK9 (ng/ml) 208 [161–264] 208 [162–262] 206 [161–264] 211 [153–271] 0.999
Total Cholesterol (mg/dl) (mg/dl) 189 [165–215] 190 [166–217] 185 [161–213] 186 [165–212] 0.158
HDL Cholesterol (mg/dl) 37 [31–45] 38 [32–45] 36 [30–44] 37 [30–45] 0.006
LDL Cholesterol (mg/dl) 112 [91–135] 112 [90–136] 112 [90–136] 112 [91–135] 0.936
Triglycerides (mg/dl) 150 [112–202] 150 [113–201] 150 [107–204] 148 [113–201] 0.932
Apo A-I (mg/dl) 127 [113–144] 129 [114–147] 122 [107–139] 125 [113–143] 0.001
Apo B (mg/dl) 103 [87–118] 102 [87–118] 103 [87–119] 103 [87–118] 0.957
hsCRP (mg/l) 3.7 [1.5–9.0] 3.0 [1.2–8.0] 5.6 [2.2–11.4] 4.0 [2.0–10.3] <0.001
Statin (yes) 721 (50%) 478 (50%) 157 (47%) 86 (53%) 0.387
CVD: cardiovascular (disease); BMI: body mass index; BP: blood pressure; GFR: glomerular ﬁltration rate; UAE: urinary albumin excretion; PCSK9:
proproteinconvertase subtilisin/kexin type 9; Apo A-I, B: apolipoprotein A, B; hsCRP: high-sensitivity C-reactive protein. Data are presented as numbers
(percentages) or median and interquartile range as appropriate. P-Values in italics are signiﬁcant by Jonckheere-Terpstra test for trend.
doi:10.1371/journal.pone.0146920.t005
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Discussion
The two main findings obtained in the two study cohorts are that the degree of renal function
impairment has no effect on total PCSK9 plasma concentrations. In addition, PCSK9 levels did
not predict cardiovascular outcomes in patients with GFR between 15 and 90 ml/min/1.73m2.
To the best of our knowledge this is by far the largest analysis of PCSK9 plasma concentra-
tions in patients with decreased GFR accompanied by validation in an independent cohort.
In cross-sectional analyses, PCSK9 was associated with BMI, total cholesterol, Apo B, Apo
A-I and triglycerides in the overall CARE FOR HOMe cohort, which is in line with findings
from the community-based Dallas Heart Study [20]. Statins increase PCSK9 levels by activating
the sterol regulatory element-binding protein-2 (SREBP2), which in turn increases expression
of PCSK9 [11,21]. Therefore, patients not on statins and statin-users were assessed separately.
In these analyses, the associations between PCSK9 and other lipid parameters remained robust.
As expected, we found higher PCSK9 levels among statin users compared to non-statin users.
Findings obtained from LURIC were consistent. We therefore conclude that kidney function,
assessed as GFR, has no major impact on PCSK9 concentrations.
The lack of an association between PCSK9 levels with CV outcome in patients with
decreased GFR differs from findings in the general population where genetically determined
lower PCSK9 levels are associated with lower LDL-C levels and consecutively lower CV risk in
the Atherosclerosis in Risk in Communities study (ARIC) [22]. Similarly, PCSK9 correlates
with CV risk in patients with stable coronary artery disease [23]. Of note, the ARIC study
enrolled a study population in the setting of primary prevention and no information on kidney
function was given in this analysis [22], whereas in the cohort of patients with stable coronary
artery disease CKD was defined as an exclusion criterion [23]. In contrast, the CARE FOR
HOMe study represents a referred CKD patient population with 30% of patients having preva-
lent CV disease. Therefore differences in study design and study populations might account for
these different findings, since patients with CKD are characterized by specific metabolic and
lipidologic alterations.
Fig 5. Association of PCSK9 tertiles with cardiovascular death in LURIC participants; Kaplan-Meier
analysis followed by log-rank test.
doi:10.1371/journal.pone.0146920.g005
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Of note, proteinuria is a further important modifier of uremic dyslipidemia leading to a dis-
tinct dyslipidemia in CKD patients characterised by increased total- and LDL cholesterol [7].
Two previous reports in smaller groups (n = 15 Korean patients with nephrotic syndrome, i.e.
proteinuria>3.5g/d, and n = 39 patients from the Netherlands with protein excretion of 1.9
[0.9–3.3] g/day) of patients with marked proteinuria observed rises in PCSK9 [24,25]. We did
not find a correlation between urinary albumin excretion and PCSK9 levels. Of note, the level
of urinary albumin excretion was only in the range of microalbuminuria in CARE FOR HOMe
(median: 35, IQR [8–193] mg/g creatinine) thus making it difficult to compare these two stud-
ies with CARE FOR HOMe. These studies are complemented by a third study in 66 haemodia-
lysis patients in whom PCSK9 concentrations were measured and compared to non-CKD
patients [26]. Approximately half of the haemodialysis patients were taking statins; the overall
haemodialysis cohort had significantly lower LDL-C levels and lower PCSK9 concentrations
compared to non-CKD patients, however when stratifying haemodialysis patients according to
statin intake, PCSK9 concentrations between haemodialysis patients on statins and non-CKD
patients did not differ significantly.
Taken together, based on the lack of an effect of GFR on PCSK9 in CARE FOR HOMe and
LURIC we would expect equal LDL-C lowering in CKD compared to non-CKD populations by
pharmacologic inhibition of PCSK9.
Study strengths and limitations
Statin intake in nearly half of the study participants in CARE FOR HOMe and LURIC could be
regarded as a limitation, since statins modify PCSK9 concentrations. However, analyses strati-
fied according to statin intake did not materially change the results. More importantly, this
high prevalence of statin intake represents current medical practice in a real life setting in
which anti-PCSK9 agents potentially would be used.
Outcome definitions in CARE FOR HOMe and LURIC differed because the studies were
performed independently, which is a potential limitation of our analysis. As we present data
from cohort studies we are not able to draw a conclusion on potential mechanisms and
causality.
A particular strength of our study is complete follow-up in both studies and validation in a
second independent cohort of LURIC participants with GFR between 15 and 90 ml/min/
1.73 m2. Obviously, the question whether inhibition of PCSK9 is able to reduce CV events in
patients with impaired renal function cannot be answered from our data.
Conclusions
In conclusion, our study confirms that patients with decreased GFR present with specific lipid
abnormalities that differ from other secondary prevention populations. Since renal impairment
can predispose to statin side effects and increased risk of statin intolerance [27], alternative
LDL lowering drugs might be useful for patients with decreased GFR.
Whether PCSK9 inhibitors represent such an alternative should be prospectively tested.
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